“An Efficacy and Safety Comparison of Regorafenib and Nivolumab in Unresectable Hepatocellular Cancer Patients: A Systematic Review”. Acta Medica Academica 53, no. 1 (April 30, 2024): 46–58. Accessed August 16, 2025. https://www.ama.ba/index.php/ama/article/view/564.